Juda Scott
Known title: DirectorCIK: 0001767084
Juda Scott's purchase track record
How the stock did after each of Juda Scott's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 17, 2021
Stock higher 6 months later
33%
3 months: 33%
Median 6-month return
-37.2%
3 months: -17.4%
Beat the S&P 500
33%
median -29.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/25/2024 | INMB | $36K | -28.4% | -37.2% | +10.4% |
| 11/10/2023 | INMB | $49K | +75.9% | +46.1% | +18.3% |
| 11/17/2021 | INMB | $34K | -17.4% | -45.4% | -16.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INMB | ▲ Buy | Option Exercise | 14,801 | $21K | 7/2/2026 | View on chart |
| INMB | ▲ Buy | Open Market | 5,000 | $36K | 6/25/2024 | View on chart |
| INMB | ▲ Buy | Grant | 29,603 | $246K | 4/19/2024 | View on chart |
| INMB | ▲ Buy | Open Market | 7,000 | $49K | 11/10/2023 | View on chart |
| INMB | ▲ Buy | Open Market | 2,500 | $34K | 11/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
INmune Bio Announces Attendance at 2026 Maxim Growth Summit
INmune Bio said it will attend the 2026 Maxim Growth Summit. The event is a platform for biotech companies to meet investors and partners. Attendance may raise the company’s profile and open new collaboration opportunities. The stock is currently trading near the lower end of its 52‑week range.
INmune Bio Announces Attendance at 2026 Maxim Growth Summit. INmune Bio said it will attend the 2026 Maxim Growth Summit. The event is a platform for biotech companies to meet investors and partners. Attendance may raise the company’s profile and open new collaboration opportunities. The stock is currently trading near the lower end of its 52‑week range.